Novartis Annual General Meeting: Shareholders Approve All Proposed Resolutions
Basel, Switzerland, March 7, 2025 – In a well-attended Annual General Meeting (AGM) held in Basel, Novartis shareholders approved all the proposals put forth by the Board of Directors. A total of 1,693 shareholders were present at the meeting, representing approximately 57.42% of the issued shares of the pharmaceutical giant.
Key Resolutions
The following resolutions were approved:
- Re-election of Board Members: Shareholders voted to re-elect six members to the Board of Directors, including the Chairman, for another term.
- Executive Compensation: The shareholders approved the compensation report for the Executive Board and the compensation policy for the next fiscal year.
- Dividend: The shareholders agreed to a dividend payment of CHF 1.20 per share.
- Authorized Share Capital: The shareholders approved the increase of the authorized share capital to issue up to 15,000,000 new shares.
- Auditor: The shareholders confirmed the appointment of PricewaterhouseCoopers AG as the auditor for the forthcoming fiscal year.
Impact on Shareholders
The approval of the proposed resolutions, particularly the dividend payment, is a positive sign for Novartis shareholders. The dividend of CHF 1.20 per share represents a yield of approximately 3.5% based on the current share price. This payout is consistent with Novartis’ commitment to rewarding shareholders with a stable dividend, making it an attractive investment for income-focused investors.
Impact on the World
Novartis’ AGM results have little direct impact on the world, but the pharmaceutical industry as a whole could be affected by the company’s ongoing research and development efforts. Novartis is a leader in innovative treatments and has a strong pipeline of potential new medicines. This ongoing investment in research and development could lead to new treatments for diseases with high unmet medical needs, benefiting patients and healthcare systems worldwide.
Conclusion
The successful outcome of Novartis’ 2025 Annual General Meeting is a testament to the company’s strong governance and the support of its shareholders. The approval of the proposed resolutions, including the dividend payment, is a positive sign for investors. Additionally, Novartis’ ongoing commitment to research and development could lead to significant advancements in the pharmaceutical industry and benefit patients around the world.
As a responsible and innovative company, Novartis continues to prioritize the needs of its shareholders, employees, and patients. The future looks bright for this global healthcare leader.
